MX420767B - Proteina de union al factor h modificada - Google Patents

Proteina de union al factor h modificada

Info

Publication number
MX420767B
MX420767B MX2019002248A MX2019002248A MX420767B MX 420767 B MX420767 B MX 420767B MX 2019002248 A MX2019002248 A MX 2019002248A MX 2019002248 A MX2019002248 A MX 2019002248A MX 420767 B MX420767 B MX 420767B
Authority
MX
Mexico
Prior art keywords
binding protein
modified factor
fhbp
modified
factor
Prior art date
Application number
MX2019002248A
Other languages
English (en)
Spanish (es)
Other versions
MX2019002248A (es
Inventor
Tang Christoph M
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2019002248A publication Critical patent/MX2019002248A/es
Publication of MX420767B publication Critical patent/MX420767B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MX2019002248A 2016-08-31 2017-08-31 Proteina de union al factor h modificada MX420767B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1614687.0A GB201614687D0 (en) 2016-08-31 2016-08-31 fHbp scaffold
PCT/GB2017/052535 WO2018042178A1 (en) 2016-08-31 2017-08-31 Modified factor h binding protein

Publications (2)

Publication Number Publication Date
MX2019002248A MX2019002248A (es) 2019-09-18
MX420767B true MX420767B (es) 2025-02-10

Family

ID=57119942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002248A MX420767B (es) 2016-08-31 2017-08-31 Proteina de union al factor h modificada

Country Status (13)

Country Link
US (1) US12497432B2 (Direct)
EP (1) EP3506934A1 (Direct)
JP (1) JP7525093B2 (Direct)
KR (1) KR102643280B1 (Direct)
CN (1) CN109890412B (Direct)
AU (1) AU2017319218B2 (Direct)
BR (1) BR112019003957A2 (Direct)
CA (1) CA3035159A1 (Direct)
GB (2) GB201614687D0 (Direct)
IL (1) IL265078B2 (Direct)
MX (1) MX420767B (Direct)
WO (1) WO2018042178A1 (Direct)
ZA (1) ZA201901862B (Direct)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110903400A (zh) * 2019-11-08 2020-03-24 苏州微超生物科技有限公司 B群脑膜炎球菌fHBP多变体融合蛋白及其制备方法与应用
CN111533792B (zh) 2020-07-07 2020-10-16 康希诺生物股份公司 一种定点突变的载体蛋白及其在制备疫苗中的用途
US20230365979A1 (en) * 2020-09-29 2023-11-16 Idemitsu Kosan Co.,Ltd. Peptide tag and tagged protein including same
IN202321021121A (Direct) * 2023-03-24 2024-04-19

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1549338B1 (en) * 2002-10-11 2010-12-22 Novartis Vaccines and Diagnostics S.r.l. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053091A2 (en) * 2002-12-10 2004-06-24 Lorantis Ltd. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
ES2383175T3 (es) * 2003-01-30 2012-06-18 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
PL1670506T3 (pl) * 2003-10-02 2013-04-30 Novartis Ag Płynne szczepionki przeciw wielu grupom serologicznym meningokoków
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
WO2006011060A2 (en) * 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
CN101107007B (zh) * 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
CA2716212A1 (en) * 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
US8470340B2 (en) * 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
NZ595234A (en) * 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
MX2011011512A (es) * 2009-04-30 2012-02-13 Novartis Vaccines & Diagnostic Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
EP3017828A1 (en) * 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
CN102917730A (zh) * 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
US20130004530A1 (en) * 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
EP3327028B1 (en) * 2010-03-30 2022-03-16 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
CA2803239A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
JP2015505309A (ja) * 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
JP2015517089A (ja) * 2012-03-08 2015-06-18 ノバルティス アーゲー タンパク質ベースの髄膜炎菌ワクチンのためのインビトロ有効性アッセイ
SA115360586B1 (ar) * 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
BR122016004924A2 (pt) * 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
NZ630133A (en) * 2012-06-14 2016-10-28 Novartis Ag Vaccines for serogroup x meningococcus
GB201215005D0 (en) * 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
EP2964665B1 (en) * 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
US20160030544A1 (en) * 2013-03-14 2016-02-04 Isis Innovation Limited Immunogenic composition to neisseria
CA2923129C (en) * 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RS61246B1 (sr) * 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modifikovani meningokokni fhbp polipeptidi
CN106715464B (zh) * 2014-07-23 2021-03-16 奥克兰儿童医院及研究中心 因子h结合蛋白变体及其使用方法
JP2017536823A (ja) 2014-11-28 2017-12-14 ヤンセン ヴァクシーンズ アンド プリベンション ビー．ブイ． 髄膜炎ｂワクチン
WO2016132294A1 (en) * 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
US10183070B2 (en) * 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
KR20190064577A (ko) 2019-06-10
GB201614687D0 (en) 2016-10-12
AU2017319218A1 (en) 2019-04-18
EP3506934A1 (en) 2019-07-10
AU2017319218B2 (en) 2021-10-28
GB2568440A (en) 2019-05-15
NZ751995A (en) 2024-03-22
US20220112249A1 (en) 2022-04-14
GB201903866D0 (en) 2019-05-08
AU2017319218A2 (en) 2019-05-02
JP7525093B2 (ja) 2024-07-30
CA3035159A1 (en) 2018-03-08
MX2019002248A (es) 2019-09-18
CN109890412A (zh) 2019-06-14
IL265078A (Direct) 2019-04-30
IL265078B1 (en) 2023-04-01
BR112019003957A2 (pt) 2019-06-25
IL265078B2 (en) 2023-08-01
WO2018042178A1 (en) 2018-03-08
JP2019526261A (ja) 2019-09-19
US12497432B2 (en) 2025-12-16
CN109890412B (zh) 2025-04-04
GB2568440B (en) 2022-08-17
ZA201901862B (en) 2020-09-30
KR102643280B1 (ko) 2024-03-05

Similar Documents

Publication Publication Date Title
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
BR112018071678A2 (pt) compostos terapêuticos úteis para o tratamento profilático ou terapêutico de uma infecção por vírus hiv
UY37480A (es) Nuevos derivados de quinolina
MX2023003875A (es) Formulacion de una vacuna peptidica.
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX420767B (es) Proteina de union al factor h modificada
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
MX364942B (es) Peptidos antimicrobianos.
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2017003117A (es) Particula tipo virus de flavivirus.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MX2020008125A (es) Composiciones que comprenden berberina.
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
WO2016100615A3 (en) Methods and composition for neutralization of influenza
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
MX381255B (es) Vacunas contra el reovirus aviar.
EA201890209A1 (ru) Композиция, содержащая танины